Option chain shows key data for Oncternal Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Oncternal Therapeutics.

Oncternal Therapeutics (NASDAQ:ONCT) Stock, Option Chain

Oncternal Therapeutics

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

FULC

MODV

NTGR

ONCT

SMFL

Dow Surges Over 100 Points; ModivCare Shares Plummet

Crude Oil Surges 3%; Kroger Posts Upbeat Earnings

wall-street-ai17

RYDE

TNON

US Stocks Mixed; Producer Prices Increase In August

Oncternal Therapeutics, Inc. - Common Stock

Oncternal Therapeutics Inc

<ul>
<li>MSTR</li>
<li>ACHR</li>
<li>NVDA</li>
<li>$BTC</li>
<li>SMCI</li>
<li>TSLA</li>
<li>RKLB</li>
<li>CORN</li>
<li>LUNR</li>
<li>RDDT</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

$BTC

ACHR

CORN

LUNR

MSTR

NVDA

RDDT

RKLB

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 22, 2024 (Via Swaggy Stocks)

RBC Capital analyst Chris Dendrinos maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Sector Perform and lowers the price target from $85 to $71.

Price Target

Analyst Ratings

ENPH

RBC Capital Maintains Sector Perform on Enphase Energy, Lowers Price Target to $71

QMCO

Quantum Shares Halted On Circuit Breaker To The Upside, Stock Now Up 60.5%

RBC Capital analyst Walter Spracklin reiterates Canadian National Railway (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNR#TSX">CNR</a>) with a Outperform and maintains C$179 price target.

Reiteration

TSX:CNR

RBC Capital Reiterates Outperform on Canadian National Railway, Maintains C$179 Price Target

<a href="https://www.youtube.com/watch?v=xEzVDtbYYKQ" title="https://www.youtube.com/watch?v=xEzVDtbYYKQ">https://www.youtube.com/watch?v=xEzVDtbYYKQ</a>

Events

AMZN

LIVE: Jeff Bezos' Blue Origin New Shepard Mission NS-28 Webcast

Snap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) has filed a motion to dismiss a lawsuit brought by New Mexico Attorney General Raúl Torrez. The lawsuit alleges that the company&#8217;s platform <a href="https://values.snap.com/news/new-mexico-motion-to-dismiss?lang=da-DK" target="_blank" rel="noreferrer noopener">facilitates child exploitation</a>. 
Snap argues that the lawsuit misrepresents its practices and is based on flawed interpretations of internal documents and investigatory actions.
The lawsuit claims that Snap violated state laws by promoting unsafe practices through features like disappearing messages, which allegedly enable the spread of exploitative material.
Also Read: <a href="https://www.benzinga.com/news/asset-sales/24/11/42117962/starbucks-eyes-stake-sale-in-china-amid-fierce-competition-and-falling-sales" target="_blank" rel="noreferrer noopener">Starbucks Eyes Stake Sale in China Amid Fierce Competition and Falling Sales</a>
However, Snap contends that the Attorney General&#8217;s office created a decoy account that proactively engaged with inappropriate accounts, contrary to the lawsuit&#8217;s claims, the Verge <a target="_blank" href="https://www.theverge.com/2024/11/21/24302767/snap-new-mexico-attorney-general-motion-dismiss-child-exploitation" rel="noreferrer noopener">reports</a>.
Snap insists the investigation&#8217;s findings are inaccurate and highlights that federal law prohibits storing child sexual abuse material (CSAM) on its servers. The company maintains that it reports such content to the National Center for Missing and Exploited Children, as required by law, and that the Attorney General&#8217;s framing of its practices is misleading.
The New Mexico Department of Justice criticized Snap&#8217;s motion to dismiss, accusing the company of deflecting attention from the harm caused to children on its platform. 
A spokesperson stated, &#8220;The evidence—including Snap&#8217;s internal documents—proves the company prioritizes profits over safety.&#8221; The department emphasized the urgent need for stricter safeguards to protect young users.
Snap argues that the lawsuit conflicts with federal protections under Section 230, which shields platforms from liability for user-generated content. The company also contends that proposed age-verification mandates could violate the First Amendment. Snap describes its safety-related statements as aspirational and not legally binding guarantees of risk elimination.
Social media companies — Meta Platforms Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Facebook and Instagram, Snapchat, Elon Musk&#8217;s X, formerly Twitter and ByteDance-owned TikTok — face regulatory scrutiny <a href="https://www.benzinga.com/news/24/07/40028341/senate-set-to-approve-new-child-online-safety-bill-on-tuesday-what-it-means-for-elon-musks-x-meta-sn" target="_blank" rel="noreferrer noopener">over child safety concerns</a>.
Snap posted a <a href="https://www.benzinga.com/news/earnings/24/10/41612544/snap-q3-earnings-revenue-beat-eps-beat-500m-buyback-ai-update-and-more" target="_blank" rel="noreferrer noopener">third-quarter revenue</a> of $1.373 billion, exceeding the $1.358 billion consensus estimate. Adjusted earnings reached 8 cents per share, beating the 5-cent analyst estimate. Revenue increased 15%, while daily active users grew 9% to 443 million. The company reported $116 million in operating cash flow and $72 million in free cash flow. 
The quarter ended with $3.2 billion in liquidity. Snap forecasts fourth-quarter revenue of $1.51 billion—$1.56 billion, slightly below the $1.558 billion analyst estimate. The board approved a share buyback of up to $500 million.
Price Action: Snap stock is down 0.38% at $10.59 premarket at last check Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42116366/taiwan-semiconductor-plans-new-factories-annually-boosting-domestic-chip-production" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Plans New Factories To Boost Domestic Chip Production</a></li>
</ul>
Image: Shutterstock

Legal

Media

SNAP

Snap Denies Child Exploitation Allegations, Wants Lawsuit Dismissed

RBC Capital analyst Nelson Ng reiterates EverGen Infr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#TSX">EVGN</a>) with a Sector Perform and maintains C$3 price target.

TSX:EVGN

RBC Capital Reiterates Sector Perform on EverGen Infr, Maintains C$3 Price Target

In the current session, the stock is trading at $142.32, after a 2.45% increase. Over the past month, Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) stock increased by 15.96%, and in the past year, by 90.85%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732289408_0.png" alt="Past Year Chart" />

<h3>A Look at Dell Technologies P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 32.64 in the Technology Hardware, Storage &amp; Peripherals industry, Dell Technologies Inc. has a lower P/E ratio of 25.58. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732289408_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

DELL

Price Over Earnings Overview: Dell Technologies

RBC Capital analyst James McGarragle reiterates Exchange Income (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EIF#TSX">EIF</a>) with a Outperform and maintains C$71 price target.

TSX:EIF

RBC Capital Reiterates Outperform on Exchange Income, Maintains C$71 Price Target

JP Morgan analyst David Karnovsky maintains Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) with a Overweight and lowers the price target from $41 to $40.

JP Morgan Maintains Overweight on Warner Music Gr, Lowers Price Target to $40

WIIM

GRAB

Grab Holdings shares are trading lower after B of A Securities downgraded the stock from Buy to Underperform, maintaining its price target at $4.90.

JP Morgan analyst Daniel Chen maintains iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) with a Neutral and lowers the price target from $2.5 to $1.8.

JP Morgan Maintains Neutral on iQIYI, Lowers Price Target to $1.8

RBC Capital analyst Darko Mihelic reiterates Manulife Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MFC#TSX">MFC</a>) with a Outperform and maintains C$49 price target.

TSX:MFC

RBC Capital Reiterates Outperform on Manulife Financial, Maintains C$49 Price Target

A poll of Benzinga readers found that they don't believe Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) should be broken up. This comes as the Department of Justice (DOJ) suggested divesting the Chrome browser to <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">break a search monopoly.</a>
What Happened: Google parent Alphabet has long <a href="https://www.benzinga.com/government/21/07/22094354/could-new-justice-department-hire-lead-to-google-breakup">been a target</a> of potential antitrust investigations due to the company's large market share in online search.
The DOJ recommended that Google share search data with competitors to foster fair competition. The department also said Google should consider selling its Android operating system.
"Google's unlawful behavior has deprived rivals not only of critical distribution channels but also distribution partners who could otherwise enable entry into these markets by competitors in new and innovative ways," the DOJ&nbsp;said in a statement.
A recent poll of Benzinga readers found that they don't believe Alphabet should be split up.
"Should the Department of Justice break up Alphabet (Google)?" Benzinga asked.
The results were:
<ul>
<li>Yes: 36%</li>
<li>No: 64%</li>
</ul>
While the DOJ is targeting Chrome as the potential unit to be divested, Benzinga readers have other preferences.
"Which part of Alphabet would you most want to invest in if it splits up," Benzinga asked.
The results were:
<ul>
<li>YouTube: 43%</li>
<li>Google Search: 31%</li>
<li>Android: 17%</li>
<li>Chrome: 9%</li>
</ul>
Benzinga readers ranked YouTube as the top choice for a standalone unit, while Chrome was the least favored.
Read Also: <a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale">Alphabet Bleeds Over $120 Billion In Market Value, Eyes Worst Day In 10 Months After DOJ Demands Google Chrome Sale</a>
Why It's Important: While Alphabet likely does not want to split up or sell any of its units, investors could end up the winners <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40378964/google-stock-swings-on-doj-investigation-analyst-says-googl-is-worth-more-in-pieces">according to analysts.</a>
Jefferies analyst Brent Thill recently said that a breakup or business separation could be good for shareholders.
&#8220;We don&#8217;t believe a full breakup would happen. Even if it did, it would be good for shareholders because the sum of the parts is greater than the whole,&#8221; Thill&nbsp;<a href="https://x.com/YahooFinance/status/1823722376716280107" target="_blank" rel="noreferrer noopener">told&nbsp;</a>Yahoo Finance.
Needham analyst Laura Martin has been emphasizing for months that a forced breakup of Alphabet could lead to a significantly higher valuation.
&#8220;We believe that GOOGL is worth more in pieces than together, so we welcome regulators&#8217; attempts to break up GOOGL,&#8221; Martin said in a new investor note.
A break-up could put a spotlight on the valuation of video platform YouTube, Martin said.
&#8220;We calculate that YouTube would be valued between $455B-$643B if separately traded.&#8221;
Martin said Alphabet shares would likely trade higher if the company breaks up because investors would be willing to pay more for &#8220;pure-play assets,&#8221; more data points could be publicly shared, and employees would receive shares in business lines they directly impact.
Martin has a Buy rating on Alphabet and price target of $210.
GOOG Price Action: Alphabet stock trades at $167.81 Friday versus a 52-week trading range of $129.40 to $193.31. Alphabet stock is up 21.3% year-to-date, trailing the 25.6% gain of the SPDR S&amp;P 500 ETF Trust, which tracks the S&amp;P 500.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42131274/why-googles-chrome-battle-isnt-just-about-search-gene-munster-calls-it-a-tough-day-for-big-tech-on-the-regulatory-front">Google&#8217;s Chrome Battle Goes Beyond The Browser: Gene Munster Outlines Wider Implications Of DOJ Going After The Search Giant</a></li>
</ul>
The study was conducted by Benzinga from Nov. 21 through Nov. 22, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 88 adults.
Photo: Shutterstock

Exclusives

Tech

GOOG

GOOGL

DOJ Targets Google Chrome, Poll Shows 64% Oppose Alphabet Breakup: YouTube Seen As Top Prize

Super Micro Computer shares are trading higher. The company on Wednesday announced it submitted a compliance plan to Nasdaq.

U.S. stocks traded higher this morning, with the Dow Jones index gaining by more than 300 points on Friday.
Following the market opening Friday, the Dow traded up 0.72% to 44,184.62 while the NASDAQ rose 0.07% to 18,985.33. The S&amp;P 500 also rose, gaining, 0.35% to 5,969.29.
Check This Out: <a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a>
Leading and Lagging Sectors Consumer staples shares rose by 1% on Friday.
In trading on Friday, communication services shares fell by 0.4%.
Top Headline
Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) reported better-than-expected earnings for its second quarter and raised its outlook for FY24 gross margin.
&nbsp;The company reported quarterly earnings of 54 cents per share, which beat the analyst consensus estimate of 40 cents per share.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>SKK Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKK#NASDAQ">SKK</a>) shares shot up 76% to $1.95 after declining around 75% on Wednesday.</li>
<li>Shares of DevvStream Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEVS#NASDAQ">DEVS</a>) got a boost, surging 77% to $0.8931.</li>
<li>Replimune Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) shares were also up, gaining 48% to $16.37 after the company on Thursday announced it received breakthrough therapy designation status for RP1 and will submit an RP1 biologics license application to the FDA under an accelerated approval pathway.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares dropped 52% to $6.53 after the company announced the pricing of a $9 million underwritten public offering.</li>
<li>Shares of Aptose Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) were down 44% to $0.1374 after the company announced the pricing of an $8 million public offering.</li>
<li>Cemtrex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) was down, falling 42% to $0.1148 after the company announced its board approved a 1-for-35 reverse stock split.</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $70.67 while gold traded up 0.9% at $2,697.70.
Silver traded up 1.2% to $31.33 on Thursday, while copper fell 0.8% to $4.0910.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.2%, Germany's DAX gained 0.9% and France's CAC 40 rose 0.7%. Spain's IBEX 35 Index rose 0.2%, while London's FTSE 100 gained 1.4%.
The S&amp;P Global UK composite PMI declined to 49.9 in November versus 51.8 in the previous month, while Eurozone composite PMI dipped to 48.1 in November from 50 in the prior month.
Asia Pacific Markets
Asian markets closed mixed on Friday, with Japan's Nikkei 225 gaining 0.68%, Hong Kong's Hang Seng Index falling 1.89%, China's Shanghai Composite Index dipping 3.06% and India's BSE Sensex gaining 2.54%.
Economics
<ul>
<li>The S&amp;P Global US Services PMI climbed to 57 in November versus 55 in the previous month, while manufacturing PMI increased to 48.8 in November from 48.5 in the previous month.</li>
<li>The University of Michigan consumer sentiment for the US fell to 71.8 in November versus a preliminary reading of 73.</li>
<li>The year-ahead inflation expectations in the U.S fell to 2.6% in November from 2.7% in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42135946/wall-streets-most-accurate-analysts-give-their-take-on-3-industrials-stocks-with-over-3-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Industrials Stocks With Over 3% Dividend Yields</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

AMIX

APTO

CETX

DEVS

REPL

Dow Jumps 300 Points; Gap Posts Upbeat Earnings

RBC Capital analyst Arthur Nagorny reiterates Mattr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MATR#TSX">MATR</a>) with a Outperform and maintains C$18 price target.

TSX:MATR

RBC Capital Reiterates Outperform on Mattr, Maintains C$18 Price Target

Stock Split

J-Long Group Announces 1-For-10 Reverse Stock Split

JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Overweight and lowers the price target from $45 to $15.

JP Morgan Maintains Overweight on Evolent Health, Lowers Price Target to $15

Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) shares are trading higher on Friday. The company has agreed to sell its Personal Protective Equipment (PPE) business to Protective Industrial Products, Inc. (PIP) for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42135452/honeywell-to-sell-personal-protective-equipment-business-to-protective-industrial-products" rel="noreferrer noopener">$1.325 billion in an all-cash deal</a>.
This move aligns with Honeywell&#8217;s strategy to streamline its portfolio, focusing on core businesses and pursuing high-return acquisitions that support its three key megatrends: automation, the future of aviation, and energy transition.
This sale follows Honeywell&#8217;s 2021 divestiture of its Lifestyle and Performance Footwear Business to Rocky Brands for $230 million, marking the company&#8217;s exit from the PPE sector.
However, Honeywell will retain its gas detection portfolio within the Industrial Automation segment.
The sale of the PPE business is expected to close in the first half of 2025, pending customary conditions.
Vimal Kapur, Chairman and CEO of Honeywell said, &#8221;Now with this transaction, the business will be positioned to accelerate its growth trajectory as it benefits from Odyssey&#8217;s historic investing in the PPE sector and scaling similar businesses&nbsp;to expand into new products, geographies and end markets.&#8221;
&#8220;As we continue to simplify and optimize Honeywell&#8217;s portfolio, the sale of the PPE business will enable us to further strengthen our core business in alignment with our three compelling megatrends.&#8221;
&#8221;The combination of today&#8217;s announcement, with the strategic acquisitions we have made over the past year, positions us to continue to drive profitable growth and strong cash generation while creating compelling long-term value for our shareowners.&#8221;
Last month, Honeywell announced a plan to spin off its Advanced Materials business into an independent, U.S. publicly traded company, which is targeted to be <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41223435/honeywell-announces-plan-to-spin-off-advanced-materials-business-to-shareowners" rel="noreferrer noopener">completed by the end of 2025 or early 2026.</a>
Honeywell held cash and equivalents of about&nbsp;$10.6 billion as of <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41516652/honeywells-mixed-q3-eps-beats-misses-on-sales-and-lowers-fy24-revenue-outlook" rel="noreferrer noopener">September 30, 2024</a>.
Investors can gain exposure to the stock via&nbsp;Amplify CWP Enhanced Dividend Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIVO#NYSE">DIVO</a>) and&nbsp;Invesco Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPA#NYSE">PPA</a>).
Price Action: HON shares are up 1.01% at $228.38 at the last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42137748" target="_blank" rel="noreferrer noopener">Amid Ongoing Browser Antitrust Scrutiny In US, UK Might Be Next To Challenge Apple And Google&#8217;s Duopoly</a></li>
</ul>

Large Cap

Asset Sales

DIVO

Honeywell Cashes Out: $1.325 Billion PPE Business Sale Fuels Bold Portfolio Transformation

Oncternal Therapeutics Q2 2024 Earnings Preview

Oncternal Therapeutics GAAP EPS of -$2.89 beats by $0.14, revenue of $0.8M beats by $0.64M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Oncternal Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/onct-stock-quote/">ONCT</a>) just reported results for the second quarter of 2024.<ul><li>Oncternal Therapeutics reported earnings per share of -$2.89. This was above the analyst estimate for EPS of -$3.10.</li><li>The company reported revenue of $801,000.</li><li>This was 233.75% better than the analyst estimate for revenue of $240,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/onct-stock-earnings-oncternal-therapeutics-for-q2-of-2024/">ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024

Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript

Oncternal plunges on portfolio shakeup

Oncternal Therapeutics ( ($ONCT) ) has shared an announcement. Oncternal Therapeutics, Inc. is reducing its workforce by 37%, approximately 10 empl...

Oncternal Therapeutics Restructures Amid Clinical Setbacks

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Oncternal Therapeutics (ONCT) has disclosed a new risk, in the Employment / Personnel category. Oncternal Therapeutics faces potential risks associ...

Oncternal Therapeutics Faces Workforce Reduction Challenges: Potential Risks and Implications

Oncternal Therapeutics ( ($ONCT) ) has provided an update. Oncternal Therapeutics, Inc. is undergoing a significant workforce reduction, effective ...

Oncternal Therapeutics Announces Workforce Reduction and Executive Changes

Oncternal Therapeutics ( ($ONCT) ) has released its Q3 earnings. Here is a breakdown of the information Oncternal Therapeutics presented to its inv...

Oncternal Therapeutics Reports Q3 2024 Earnings

ALLK

APVO

CNSP

CYCC

GNPX

IMUX

MBIO

SYRS

Press Releases

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Health Care

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics to Present in JonesTrading Healthcare Summit

Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

General

Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Comments

Oncternal Therapeutics

Oncternal Therapeutics (ONCT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga